Menu
Not yet recruiting NCT07263165

Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block

No phase Interventional Opioid Consumption, Postoperative

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dexmedetomidine.
Who it may be relevant to
Registry conditions: Opioid Consumption, Postoperative. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Effect of Adding Dexmedetomidine as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery. A Prospective Randomized Clinical Trial

Overview

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.

Detailed description

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery. A prospectiverandomized clinical trial

Interventions

  • Drug Dexmedetomidine
    Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block

Primary outcome measures

  • Total Postoperative Opioid Consumption (mg of morphine equivalents) [Time frame: 24 hours postoperative.]
Secondary outcome measures (5)
  • Postoperative Pain Intensity Using the Visual Analog Scale (VAS 0-10) [Time frame: 2, 4, 6, 12, 18, and 24 hours postoperative.]
  • Time to First Request for Rescue Analgesia. [Time frame: 24 hour postoperative]
  • Number of Participants with Adverse Effects [Time frame: first 2 hours postoperative.]
  • patient satisfaction score [Time frame: 1 hour postoperative]
  • Block-related complications. [Time frame: intraoperative and 24 postoperative]

Eligibility criteria

Inclusion criteria

  • Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy).
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Body mass index (BMI) between 18-35 kg/m².

Exclusion criteria

  • Patient refusal.
  • Allergy to local anesthetics or dexmedetomidine.
  • Coagulopathy (INR >1.5, platelet count <100,000/mm³).
  • Infection at the injection site.
  • Severe cardiopulmonary, renal, or hepatic dysfunction.
  • Chronic opioid use (>30 mg morphine equivalents daily for >3 months).
  • Pregnancy or lactation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07263165 · External Ob. intercostal block

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗